CCM
KLRS

Coldstream Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Coldstream Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-208
Closed -$1.67K – 3526
2025
Q1 		$1.67K Buy
+208
New +$2.04K ﹤0.01% 3060

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Coldstream Capital Management's KLRS Position: Q2 2025 in Review

Coldstream Capital Management sold out of Kalaris Therapeutics (KLRS) in Q2 2025, closing a stake of 208 shares — an estimated $1.67K sold.

Coldstream Capital Management first reported a position in KLRS in Q1 2025 and held it in 1 quarter. The position peaked at $1.67K in Q1 2025. 30 funds tracked by Wall St. Rank hold KLRS as of Q2 2025.

  • Coldstream Capital Management reported no remaining Kalaris Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 208 Kalaris Therapeutics shares in Q2 2025, an estimated $1.67K.
  • Coldstream Capital Management first reported a position in Kalaris Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Kalaris Therapeutics position peaked at $1.67K in Q1 2025.
  • 30 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.